New molecular targets in canine hemangiosarcoma—Comparative review and future of the precision medicine
Veterinary and Comparative Oncology · 2023
DOI: 10.1111/vco.12917 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Veterinary and Comparative Oncology, 2023. Verfasst von Karolina Małgorzata Kapturska und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland. Hauptthemen laut MEDLINE: Hemangiosarcoma, Dog Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 299 Literaturangaben. Gefördert von: 'Implementation Ph.D. Programme' Wrocław University of Environmental and Life Sciences Doctoral School cooperation with Ministry of Science and Education.
Abstract (Originalsprache)
Human angiosarcoma and canine hemangiosarcoma reveal similarities not only in their aggressive clinical behaviour, but especially in molecular landscape and genetic alterations involved in tumorigenesis and metastasis formation. Currently, no satisfying treatment that allows for achieving long overall survival or even prolonged time to progression does not exist. Due to the progress that has been made in targeted therapies and precision medicine the basis for a new treatment design is to uncover mutations and their functions as possible targets to provide tailored drugs for individual cases. Whole exome or genome sequencing studies and immunohistochemistry brought in the last few years important discoveries and identified the most common mutations with probably crucial role in this tumour development. Also, despite a lack of mutation in some of the culprit genes, the cancerogenesis cause may be buried in main cellular pathways connected with proteins encoded by those genes and involving, for example, pathological angiogenesis. The aim of this review is to highlight the most promising molecular targets for precision oncology treatment from the veterinary perspective aided by the principles of comparative science. Some of the drugs are only undergoing laboratory in vitro studies and others entered the clinic in the management of other cancer types in humans, but those used in dogs with promising responses have been mentioned as priorities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland.
- Veterinary Clinic NEOVET s.c. Hildebrand, Jelonek, Michalek-Salt, Wroclaw, Poland.
ORCID-Profile: Aleksandra Pawlak
Förderung
- 'Implementation Ph.D. Programme' Wrocław University of Environmental and Life Sciences Doctoral School cooperation with Ministry of Science and Education
Zitieren
APA
Kapturska, K. M., & Pawlak, A. (2023). New molecular targets in canine hemangiosarcoma—Comparative review and future of the precision medicine. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.12917
Vancouver
Kapturska KM, Pawlak A. New molecular targets in canine hemangiosarcoma—Comparative review and future of the precision medicine. Veterinary and Comparative Oncology. 2023. doi:10.1111/vco.12917
BibTeX
@article{Kapturska2023,
author = {Kapturska, Karolina Małgorzata and Pawlak, Aleksandra},
title = {New molecular targets in canine hemangiosarcoma—Comparative review and future of the precision medicine},
journal = {Veterinary and Comparative Oncology},
year = {2023},
doi = {10.1111/vco.12917}
}
EUVIMED